+34 9340006100 -ext. 437807-info@nanbiosis.com

03 Feb

“CIBER is collaboration”

CIBER Centro de Investigación Biomédica en Red (Consortium for Biomedica[...]

02 Feb

Advancing a novel nano-pharmaceutical towards clinical translation

Prof Nora Ventosa, Scientific Director of NANBIOSIS U6 “Biomaterial Processing[...]

SEE ALL NEWS

Cutting-edge Biomedical Solutions

What are our  “Cutting-Edge Biomedical Solutions”

Integrated solutions to advanced challenges faced by biomedical researchers in nanomedicine, tissue engineering and regenerative medicine, diagnostic and medical device, that includes design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological point of view up to preclinical validation.

Complementing our list of “Cutting-Edge Biomedical Solutions” we offer a “Quallity Control and Regulatory Affair” Advisory Service

Contact us

 

Customized Biomolecules

Customized biomolecules production & validation

Design & Production of biomolecules: Customized design and production services of biological molecules for Tissue Engineering, Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors reagents. Applications such as therapeutic agents, targeting, surfaces functionalization (tissue engineering or scaffolds and biosensors), IVD reagents.

Validation: Purification, characterization, chemical modifications and preservation of the developed biomolecules. Assays development and validation. Biomolecules functionalization and up-scaling.

Main Services are:

  • Production of antibodies and design and synthesis of haptens
  • Production of peptides. Development and design of specific peptides to be bound to therapeutic nanoconjugates or peptide drug conjugates.
  • Production of Anti-peptide Antibodies as a diagnostic tool.
  • Production of recombinant proteins: “Tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems.
  • Production of Protein-only nanomaterial platforms and their characterization for biomedicine.
  • Production of Oligonucleotides and its derivatives: Microgram to milligram amounts of DNA and RNA derivatives carrying modifications as well as oligonucleotide conjugates carrying lipids, membrane-receptor ligands, carbohydrates and peptides designed for therapeutic or diagnostics.
Contact us

Customized nanomedicines production & Preclinical Validation
 

Customized nanomedicines production & Preclinical Validation

Design & Production of nanomedicines: Supply nanomaterials, nanoconjugates and nanoencapsulation of active ingredients for applications in Nanomedicine: therapy, drug delivery, contrast agents (MRI, fluorescence) , theragnostic & reagents.

Preclinical Validation: Preclinical characterisation of nanomedicines including physicochemical properties, in vitro and in vivo biological properties. Immunology, toxicology and efficacy with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions. Biodistribution and metabolization follow up in animal models by NMR spectroscopy in tissues & biofluids.

Main Services are:

Customized biomaterials production & Preclinical Validation

Customized biomaterials production & Preclinical Validation 

Design & Production of biomaterials: Design and production of scaffolds for tissue engineering using 3D printing technologies and others.

Preclinical Validation: Preclinical validation of biomaterials, implants and surface coatings including surface and mechanical characterization and in vitro, biofilm and antibacterial properties studies of implants and in vivo biological properties with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions.

Main Services are:

  • Production of biomaterials and scaffolds by 3D printing. Scaffolds and biomaterials production using different materials and  techniques including the 3D bioprinting for regenerative medicine and tissue engineering.
  • Physicochemical characterization of biomaterials: mechanical, surface composition and surface characteristics by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter.
  • Surface and Mechanical Characterization of Biomaterials, including standard mechanical and surface composition studies.
  • In vitro Characterization of Biomaterials: toxicity assays, bacterial adhesion and biofilm formation and antibacterial characteristics of materials by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter.
  • In vivo Characterization of Biomaterials: NANBIOSIS offers a preclinical study plan tailored to meet the demands of each biomaterial based medical product, developed in collaboration with the user and starting from a set of basic analytical tests to more sophisticated experiments under either GLP and non-GLP conditions.
  • In silico modelling: NANBIOSIS supplies expertise in customized computational solutions for different tissues (cardiovascular system, human eye and others). Mainly expertise in the numerical-experimental models and experimental electrophysiology processing and modelling in cardiology and modelling of functional behaviour of tissues and organs is offered.

Contact us

Diagnostics Devices Development & Validation

Diagnostics Devices Development & Validation 

In vitro diagnostics & biomarkers & organ-on-a chip: Development and validation of prototypes, biosensing devices, organ-on-a chip devices for diagnostic. Production of bioreceptors against identified biomarkers. Discovery of biomarkers for diagnostic, follow-up and prognostic of diseases by NMR spectroscopy in biofluids and tissues.

In vivo Bioimaging diagnostics & Validation: In vivo validation of contrast agents and development of nanoconjugates as contrast agents for MRI and fluorescence.

Main services are:

  • Affinity biomolecules production for diagnostics: production and characterization of affinity receptors and reagents for in vitro diagnostic devices.
  • In vitro diagnostic Development & Validation. Core Facilities in nanofabrication, biosensors development, microfluidics, bionano characterization and micro-nano technologies in Spain. NANBIOSIS supported the whole MNBS fabrication steps of the device and validation procedures of the developed IVD.
  • Biomarker’s discovery: Discovery and quantification of biomarkers by NMR. Singular facilities for acquiring unique metabolic profiles of biofluids, cell lines and tissues by NMR techniques and others.
  • Organ-on-a-chip devices development & Validation. Experts in microfluidics for the device’s development & validation. The customization of the technology needed, the design of the devices, the complete fabrication process, their encapsulation, micro electrodes incorporation and the characterization and test up to the technological support on the experimental uses. Several organ-on-a-chip devices have been developed based on organoids and IPScells, scaffolds and others).
  • Data-enabled techniques: Experts related to the use of personalized virtual and augmented reality for pre-intraoperative planning, data-intensive methodologies, artificial intelligence techniques (machine learning) for virtual patients’ personalization (digital twins).
  • Nanoparticles as contrast agents for MRI and OCT: NANBIOSIS approach offers novel synthetic strategies and experimental setup for the advanced preparation of a wide range of nanoparticles for MRI contrast agents.
  • Nanoconjugates for fluorescence: NANBIOSIS approach offers novel synthetic strategies and experimental setup for the advanced preparation of a wide range of nanoparticles for fluorescence.
  • Validation of NPs for glioma: analysis of potential therapeutic agents to be used in glioblastoma.
  • Validation of Contrast Agents for MRI: a complete pathway for synthesis, physicochemical characterization, biocompatibility and toxicity evaluation. Preclinical validation through magnetic resonance of new compounds with potential for contrast agents in magnetic resonance imaging (MRI).
Contact us

About Us

The Spanish Strategy for Science, Technology and Innovation 2013-2020, adopted by the Council of Ministers on February 1st, 2013, includes the update of the “National Scientific and Technological Infrastructure Map (ICTS)”  for the period 2013-2016, and actualized for 2016-2020 and 2021-2024. The so-called singular scientific and technical infrastructures (ICTS) are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation. These are facilities of different scientific areas ranging from the life sciences to astrophysics or engineering, distributed throughout the Spanish territory. NANBIOSIS has been recognized by the Spanish Government as one of these 29 UNIQUE existing ICTS, which are OPEN to competitive access to users of the whole research community in the public and private sector.

Order request Access protocolSurvey

Next Events

Our figures

0

Units

0

Scientists linked to ICTS

0

Projects since 2008

0

Services since 2008

0

Publications since 2008

0

M€ investment